Endorsed Technology Appraisals 2011/2012 | Department of Health

Endorsed NICE Technology Appraisals 2011/13 under the Previous Process

Details

Endorsed Under the Previous Process

The following NICE Technology Appraisals were endorsed by DoH during 2011-12 under the process which was in place prior to 28 September 2011

Documents

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA86 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours - HSC SQSD) (NICE) 28/2011
PDF (346 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA191 - Capecitabine for the treatment of Advanced Gastric Cancer - HSC (SQSD) (NICE) 14/11
PDF (336 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA192 - Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer - HSC (SQSD) (NICE) 30/2011
PDF (342 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA202 - Ofatumumab for the Treatment of Chronic Lymphocytic Leukaemia Refractory to Fludarabine and Alemtuzumab - HSC (SQSD) (NICE) 16/2011
PDF (323 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA204 - Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women - HSC (SQSD) (NICE) 17/2011
PDF (328 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA209 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours (Part update of NICE TA86) - HSC (SQSD) (NICE) 29/2011
PDF (345 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA212 - Colorectal Cancer (metastatic) - Bevacizumab in combination with Oxaliplatin & either 5-fluorouracil plus Folinic Acid or Capecitabine - HSC (SQSD) (NICE) 19/2011
PDF (337 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA213 - Aripiprazole for Schizophrenia in People Aged 15-17 Years - HSC (SQSD) 25/2011
PDF (336 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA214 - Bevacizumab in Combination with a Taxane for the First-line Treatment of Metastatic Breast Cancer - HSC (SQSD) (NICE) 20/2011
PDF (324 KB)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA217 - Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease - HSC (SQSD) (NICE) 32/2011
PDF (213 KB)

Help viewing documents